XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination (Tables)
12 Months Ended
Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Total Purchase Price Consideration
The total purchase consideration was comprised of the following (in thousands):

Cash consideration for Antares shares outstanding as of May 24, 2022$956,886 
Consideration for Antares equity compensation awards (a)
45,828 
Consideration for seller transaction costs paid by Halozyme22,906 
Consideration related to Antares closing indebtedness settled by Halozyme19,683 
Cash consideration related to cash bonus awards paid by Halozyme
365 
Total purchase consideration
$1,045,668 
(a) Consideration for Antares equity compensation awards consists of $32.2 million paid for vested equity awards as well as $13.6 million paid for the pre-combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable to the post-combination period of $8.7 million is included in our consolidated statements of income in twelve months ended December 31, 2022.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed As a result, the preliminary estimates may be revised during the measurement period. These differences could change the value of the intangible assets acquired, the contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of operations and financial position.
Amounts (in thousands)
Amounts recognized as of Acquisition date (as initially reported)Measurement period adjustmentAmounts recognized as of Acquisition date (as adjusted )
Total purchase consideration, net of $46,548 cash acquired
$999,120 $— $999,120 
Assets:
Short-term investments498 — 498 
Accounts receivable, net82,160 — 82,160 
Inventories, net34,379 (6,311)28,068 
Prepaid expenses and other assets5,241 — 5,241 
Property and equipment, net28,661 — 28,661 
Intangibles, net987,500 (397,700)589,800 
Liabilities:— 
Accounts Payable7,197 — 7,197 
Accrued expenses33,705 7,949 41,654 
Deferred revenue, current portion2,509 — 2,509 
Deferred revenue, net of current portion1,207 — 1,207 
Deferred tax liabilities, net159,094 (88,092)71,002 
Other long-term liabilities135,088 (114,300)20,788 
Net assets acquired, excluding goodwill$799,639 $(209,568)$590,071 
Goodwill$199,481 $209,568 $409,049 
Schedule of Acquired Finite-Lived Intangible Assets by Major Class Useful lives and preliminary values are presented in the table below.
Amount (in thousands)Useful life (years)
Auto-Injector technology platform$402,000 7
XYOSTED proprietary product136,200 10
TLANDO product rights2,900 10
ATRS-1902 (IPR&D)48,700 Indefinite
Estimated fair value of intangible assets acquired$589,800 
Schedule of Acquired Indefinite-lived Intangible Assets by Major Class Useful lives and preliminary values are presented in the table below.
Amount (in thousands)Useful life (years)
Auto-Injector technology platform$402,000 7
XYOSTED proprietary product136,200 10
TLANDO product rights2,900 10
ATRS-1902 (IPR&D)48,700 Indefinite
Estimated fair value of intangible assets acquired$589,800 
Business Acquisition, Pro Forma Information (unaudited)
The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and Antares as if the companies had been combined as of the beginning of our fiscal year 2021.
Twelve Months Ended
December 31,
20222021
Total Revenues$712,683 $627,292 
Net income$218,723 $295,634